S&P 500   3,967.76 (+0.48%)
DOW   32,214.92 (+0.34%)
QQQ   310.57 (+0.26%)
AAPL   159.84 (+0.57%)
MSFT   279.85 (+0.79%)
META   206.16 (+0.92%)
GOOGL   105.17 (-0.41%)
AMZN   98.14 (-0.58%)
TSLA   190.06 (-1.12%)
NVDA   267.33 (-1.68%)
NIO   9.09 (-1.94%)
BABA   86.85 (+0.38%)
AMD   97.81 (-2.46%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   61.06 (-0.46%)
CGC   1.92 (+0.26%)
GE   91.05 (-0.59%)
DIS   94.18 (-1.72%)
AMC   4.42 (-1.12%)
PFE   40.40 (+0.55%)
PYPL   73.81 (+1.72%)
NFLX   329.50 (+2.85%)
S&P 500   3,967.76 (+0.48%)
DOW   32,214.92 (+0.34%)
QQQ   310.57 (+0.26%)
AAPL   159.84 (+0.57%)
MSFT   279.85 (+0.79%)
META   206.16 (+0.92%)
GOOGL   105.17 (-0.41%)
AMZN   98.14 (-0.58%)
TSLA   190.06 (-1.12%)
NVDA   267.33 (-1.68%)
NIO   9.09 (-1.94%)
BABA   86.85 (+0.38%)
AMD   97.81 (-2.46%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   61.06 (-0.46%)
CGC   1.92 (+0.26%)
GE   91.05 (-0.59%)
DIS   94.18 (-1.72%)
AMC   4.42 (-1.12%)
PFE   40.40 (+0.55%)
PYPL   73.81 (+1.72%)
NFLX   329.50 (+2.85%)
S&P 500   3,967.76 (+0.48%)
DOW   32,214.92 (+0.34%)
QQQ   310.57 (+0.26%)
AAPL   159.84 (+0.57%)
MSFT   279.85 (+0.79%)
META   206.16 (+0.92%)
GOOGL   105.17 (-0.41%)
AMZN   98.14 (-0.58%)
TSLA   190.06 (-1.12%)
NVDA   267.33 (-1.68%)
NIO   9.09 (-1.94%)
BABA   86.85 (+0.38%)
AMD   97.81 (-2.46%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   61.06 (-0.46%)
CGC   1.92 (+0.26%)
GE   91.05 (-0.59%)
DIS   94.18 (-1.72%)
AMC   4.42 (-1.12%)
PFE   40.40 (+0.55%)
PYPL   73.81 (+1.72%)
NFLX   329.50 (+2.85%)
S&P 500   3,967.76 (+0.48%)
DOW   32,214.92 (+0.34%)
QQQ   310.57 (+0.26%)
AAPL   159.84 (+0.57%)
MSFT   279.85 (+0.79%)
META   206.16 (+0.92%)
GOOGL   105.17 (-0.41%)
AMZN   98.14 (-0.58%)
TSLA   190.06 (-1.12%)
NVDA   267.33 (-1.68%)
NIO   9.09 (-1.94%)
BABA   86.85 (+0.38%)
AMD   97.81 (-2.46%)
T   18.59 (+0.70%)
F   11.49 (+0.61%)
MU   61.06 (-0.46%)
CGC   1.92 (+0.26%)
GE   91.05 (-0.59%)
DIS   94.18 (-1.72%)
AMC   4.42 (-1.12%)
PFE   40.40 (+0.55%)
PYPL   73.81 (+1.72%)
NFLX   329.50 (+2.85%)
NASDAQ:LFCR

Lifecore Biomedical - LFCR Price Target & Analyst Ratings

$3.08
+0.04 (+1.32%)
(As of 03/24/2023 03:46 PM ET)
Add
Compare
Today's Range
$2.76
▼
$3.14
50-Day Range
$1.67
▼
$7.25
52-Week Range
$1.52
▼
$11.95
Volume
467,759 shs
Average Volume
867,766 shs
Market Capitalization
$93.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Lifecore Biomedical Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

$9.50
208.44% Upside
High Prediction$11.00
Average Prediction$9.50
Low Prediction$8.00
TypeCurrent
3/24/22 to 3/24/23		1 Month Ago
2/22/22 to 2/22/23		3 Months Ago
12/24/21 to 12/24/22		1 Year Ago
3/24/21 to 3/24/22
Consensus Rating
Moderate Buy
N/AN/AN/A
Strong Buy
0 Strong Buy rating(s)
 N/A N/A N/A
Buy
1 Buy rating(s)
 N/A N/A N/A
Hold
1 Hold rating(s)
 N/A N/A N/A
Sell
0 Sell rating(s)
 N/A N/A N/A
Consensus Price Target$9.50$10.00N/AN/A
Predicted Upside208.44% Upside50.60% UpsideN/AN/A
Get Lifecore Biomedical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter.

LFCR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LFCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Lifecore Biomedical Stock vs. The Competition

TypeLifecore BiomedicalMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside222.03% Upside2,013.67% Upside24.47% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/20/2023Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform$10.00 ➝ $8.00+334.78%
3/20/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight
(Data available from 3/24/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












LFCR Price Target - Frequently Asked Questions

What is Lifecore Biomedical's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Lifecore Biomedical stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for LFCR. The average twelve-month price prediction for Lifecore Biomedical is $9.50 with a high price target of $11.00 and a low price target of $8.00. Learn more on LFCR's analyst rating history.

Do Wall Street analysts like Lifecore Biomedical more than its competitors?

Analysts like Lifecore Biomedical less than other Medical companies. The consensus rating for Lifecore Biomedical is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how LFCR compares to other companies.

Is Lifecore Biomedical being downgraded by Wall Street analysts?

Over the previous 90 days, Lifecore Biomedical's stock had 1 downgrade by analysts.

Does Lifecore Biomedical's stock price have much upside?

According to analysts, Lifecore Biomedical's stock has a predicted upside of 224.23% based on their 12-month price targets.

What analysts cover Lifecore Biomedical?

Lifecore Biomedical has been rated by Barrington Research, and Stephens in the past 90 days.


Stock Ratings Reports and Tools

Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
Ratings for Popular Stocks:
This page (NASDAQ:LFCR) was last updated on 3/24/2023 by MarketBeat.com Staff